Skip to main
CVS

CVS Health (CVS) Stock Forecast & Price Target

CVS Health (CVS) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 61%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CVS Health is a solid investment opportunity with its diverse healthcare services and strong financial performance, expecting a mid-teens adjusted EPS CAGR in the next three years. With a focused plan for margin recovery and prioritization of deleveraging, the company is on track to achieve $10.00 adjusted EPS by CY28. The consolidation of Oak Street Health adds potential synergies and a boost to the company's existing business lines. The company is well-positioned to generate strong cash flows and has $33.0-36.0B of cash available for flexible deployment, including share buybacks.

Bears say

CVS Health is facing significant challenges in its retail pharmacy operations due to increasing competition from online retailers and declining reimbursement rates from insurance companies. Moreover, the management's decision to acquire Aetna and Oak Street Health has increased the company's debt burden and complexity, leading to a deterioration in financial performance. The declining trends in pharmacy claims and lackluster growth prospects in other business segments further support a negative outlook for this stock. From a third person perspective, there are several key factors contributing to the analyst's negative outlook on CVS Health. These include intense competition from online retailers and lower reimbursement rates, the company's high debt burden and complexity from recent acquisitions, and declining pharmacy claims and lackluster growth prospects. These factors all point to a potential decrease in financial performance and an uncertain future for the company, leading to a negative outlook on the stock.

CVS Health (CVS) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 61% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVS Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVS Health (CVS) Forecast

Analysts have given CVS Health (CVS) a Buy based on their latest research and market trends.

According to 18 analysts, CVS Health (CVS) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $94.72, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $94.72, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVS Health (CVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.